Document Detail

The sympathetic nervous system and blood pressure in humans: implications for hypertension.
MedLine Citation:
PMID:  21734720     Owner:  NLM     Status:  MEDLINE    
A neurogenic component to primary hypertension (hypertension) is now well established. Along with raised vasomotor tone and increased cardiac output, the chronic activation of the sympathetic nervous system in hypertension has a diverse range of pathophysiological consequences independent of any increase in blood pressure. This review provides a perspective on the actions and interactions of angiotensin II, inflammation and vascular dysfunction/brain hypoperfusion in the pathogenesis and progression of neurogenic hypertension. The optimisation of current treatment strategies and the exciting recent developments in the therapeutic targeting of the sympathetic nervous system to control hypertension (for example, catheter-based renal denervation and carotid baroreceptor stimulation) will be outlined.
J P Fisher; J F R Paton
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2011-07-07
Journal Detail:
Title:  Journal of human hypertension     Volume:  26     ISSN:  1476-5527     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-12     Completed Date:  2012-11-13     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  463-75     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use
Blood Pressure* / drug effects
Central Nervous System / physiopathology
Cerebrovascular Disorders / physiopathology
Disease Progression
Drug Resistance
Hypertension / metabolism,  physiopathology*,  therapy
Inflammation / physiopathology
Renin-Angiotensin System
Sympathetic Nervous System / drug effects,  metabolism,  physiopathology*
Grant Support
HL033610/HL/NHLBI NIH HHS; PG/11/41/28893//British Heart Foundation; PG/11/47/28980//British Heart Foundation; //British Heart Foundation
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Digenic Inheritance of Mutations in the Coproporphyrinogen Oxidase and Protoporphyrinogen Oxidase Ge...
Next Document:  Effect of 12 weeks of resistance exercise on post-exercise hypotension in stage 1 hypertensive indiv...